E-LIB Suche - Ergebnisse für: Sheng, Jennifer

1

Changing the drug development and therapeutic paradigm with..:

Zheng, Songmao ; Prell, Rodney ; Sheng, Jennifer..
Clinical and Translational Science. 15 (2022) 9 - p. 2096-2104 , 2022

Link: https://doi.org/10.1111/..

2

Assessment of hyperprogression versus the natural course of..:

Kang, Yoon-Koo ; Reck, Martin ; Nghiem, Paul...
Journal for ImmunoTherapy of Cancer. 10 (2022) 4 - p. e004273 , 2022

Link: https://doi.org/10.1136/..

3

Clinical Benefit‐Risk Assessment of Nivolumab 240 mg Every ..:

Sheng, Jennifer ; Zhang, Jason ; Baudelet, Christine.
The Journal of Clinical Pharmacology. 61 (2021) 8 - p. 1045-1053 , 2021

Link: https://doi.org/10.1002/..

4

Tumor Growth Dynamic Modeling in Oncology Drug Development ..:

Al‐Huniti, Nidal ; Feng, Yan ; Yu, Jingyu (Jerry)...
CPT: Pharmacometrics & Systems Pharmacology. 9 (2020) 8 - p. 419-427 , 2020

Link: https://doi.org/10.1002/..

5

A Phase I Dose Escalation Study of the Safety, Tolerability..:

Ma, Yuxiang ; Fang, Wenfeng ; Zhao, Hongyun...
The Oncologist. 26 (2020) 4 - p. e549-e566 , 2020

Link: https://doi.org/10.1002/..

6

Population Pharmacokinetics of Ipilimumab in Combination Wi..:

Sanghavi, Kinjal ; Zhang, Jason ; Zhao, Xiaochen...
CPT: Pharmacometrics & Systems Pharmacology. 9 (2019) 1 - p. 29-39 , 2019

Link: https://doi.org/10.1002/..

7

Oncology Therapy Drugs in China, Japan, and the United Stat..:

Zhou, Li ; Higashimori, Mitsuo ; Shen, Kai...
Clinical Pharmacology & Therapeutics. 105 (2019) 6 - p. 1303-1320 , 2019

Link: https://doi.org/10.1002/..

8

Population Pharmacokinetics of Nivolumab in Combination Wit..:

Zhang, Jason ; Sanghavi, Kinjal ; Shen, Jun...
CPT: Pharmacometrics & Systems Pharmacology. 8 (2019) 12 - p. 962-970 , 2019

Link: https://doi.org/10.1002/..

9

A Phase I/II Open-Label Study of Nivolumab in Previously Tr..:

Ma, Yuxiang ; Fang, Wenfeng ; Zhang, Yang...
The Oncologist. 24 (2019) 7 - p. 891-e431 , 2019

Link: https://doi.org/10.1634/..

10

Model‐Based Population Pharmacokinetic Analysis of Nivoluma..:

Zhang, Jason ; Cai, Junliang ; Bello, Akintunde..
The Journal of Clinical Pharmacology. 59 (2019) 10 - p. 1415-1424 , 2019

Link: https://doi.org/10.1002/..

11

Challenges and Opportunities With Oncology Drug Development..:

Bajaj, Gaurav ; Gupta, Manish ; Wang, Hwei‐Gene Heidi...
Clinical Pharmacology & Therapeutics. 105 (2018) 2 - p. 363-375 , 2018

Link: https://doi.org/10.1002/..

12

Clinical Pharmacology Considerations for the Development of..:

Sheng, Jennifer ; Srivastava, Shivani ; Sanghavi, Kinjal...
The Journal of Clinical Pharmacology. 57 (2017) S10 - p. , 2017

Link: https://doi.org/10.1002/..

13

An Integrated Assessment of the Effects of Immunogenicity o..:

Passey, Chaitali ; Mora, Johanna ; Dodge, Robert...
The AAPS Journal. 19 (2017) 2 - p. 557-567 , 2017

Link: https://doi.org/10.1208/..

14

The Clinical Pharmacology of Elotuzumab:

Passey, Chaitali ; Sheng, Jennifer ; Mora, Johanna...
Clinical Pharmacokinetics. 57 (2017) 3 - p. 297-313 , 2017

Link: https://doi.org/10.1007/..

15

Elotuzumab plus lenalidomide/dexamethasone for relapsed or ..:

Dimopoulos, Meletios A. ; Lonial, Sagar ; White, Darrell...
British Journal of Haematology. 178 (2017) 6 - p. 896-905 , 2017

Link: https://doi.org/10.1111/..